
Utah Medical Products, Inc. (NASDAQ: UTMD) Stock Competitors & Peer Comparison
See UTMD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for UTMD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTMD | $69.49 | -2.07% | 198.4M | 20.59 | $3.38 | +1.77% |
| ISRG | $399.05 | -2.01% | 138.5B | 41.52 | $9.62 | N/A |
| BDX | $212.78 | +0.05% | 57.9B | 16.36 | $13.00 | +1.86% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +5.17% |
| RMD | $235.63 | -0.53% | 33.2B | 20.45 | $11.53 | +1.06% |
| MDLN | $37.04 | -2.11% | 32.6B | 27.17 | $1.36 | N/A |
| WST | $390.30 | -1.61% | 27.2B | 42.46 | $9.20 | +0.23% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $84.50 | -1.52% | 14.4B | 11.91 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +6.23% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
UTMD vs ISRG Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ISRG has a market cap of 138.5B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ISRG trades at $399.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ISRG's P/E ratio is 41.52. In terms of profitability, UTMD's ROE is +0.09%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, UTMD is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
UTMD vs BDX Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, BDX has a market cap of 57.9B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while BDX trades at $212.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas BDX's P/E ratio is 16.36. In terms of profitability, UTMD's ROE is +0.09%, compared to BDX's ROE of +0.05%. Regarding short-term risk, UTMD is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
UTMD vs BDXA Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas BDXA's P/E ratio is 45.70. In terms of profitability, UTMD's ROE is +0.09%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, UTMD is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BDXA's competition here
ResMed Inc. (NYSE: RMD)
UTMD vs RMD Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, RMD has a market cap of 33.2B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while RMD trades at $235.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas RMD's P/E ratio is 20.45. In terms of profitability, UTMD's ROE is +0.09%, compared to RMD's ROE of +0.25%. Regarding short-term risk, UTMD is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
UTMD vs MDLN Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, MDLN has a market cap of 32.6B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while MDLN trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas MDLN's P/E ratio is 27.17. In terms of profitability, UTMD's ROE is +0.09%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, UTMD is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
UTMD vs WST Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, WST has a market cap of 27.2B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while WST trades at $390.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas WST's P/E ratio is 42.46. In terms of profitability, UTMD's ROE is +0.09%, compared to WST's ROE of +0.21%. Regarding short-term risk, UTMD is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
UTMD vs HOLX Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas HOLX's P/E ratio is 31.54. In terms of profitability, UTMD's ROE is +0.09%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, UTMD is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
UTMD vs SOLV Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, SOLV has a market cap of 14.4B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while SOLV trades at $84.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas SOLV's P/E ratio is 11.91. In terms of profitability, UTMD's ROE is +0.09%, compared to SOLV's ROE of +0.03%. Regarding short-term risk, UTMD is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
UTMD vs BDXB Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas BDXB's P/E ratio is 7.60. In terms of profitability, UTMD's ROE is +0.09%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, UTMD is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
UTMD vs BAX Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, BAX has a market cap of 13.1B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while BAX trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas BAX's P/E ratio is 12.21. In terms of profitability, UTMD's ROE is +0.09%, compared to BAX's ROE of -0.12%. Regarding short-term risk, UTMD is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
UTMD vs COO Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, COO has a market cap of 11.2B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while COO trades at $58.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas COO's P/E ratio is 12.91. In terms of profitability, UTMD's ROE is +0.09%, compared to COO's ROE of +0.07%. Regarding short-term risk, UTMD is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
UTMD vs RGEN Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, RGEN has a market cap of 10.5B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while RGEN trades at $163.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas RGEN's P/E ratio is 91.00. In terms of profitability, UTMD's ROE is +0.09%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, UTMD is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
UTMD vs AVTR Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, AVTR has a market cap of 10.1B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while AVTR trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas AVTR's P/E ratio is 17.46. In terms of profitability, UTMD's ROE is +0.09%, compared to AVTR's ROE of +0.06%. Regarding short-term risk, UTMD is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
UTMD vs ATR Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ATR has a market cap of 8.9B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ATR trades at $140.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ATR's P/E ratio is 24.50. In terms of profitability, UTMD's ROE is +0.09%, compared to ATR's ROE of +0.10%. Regarding short-term risk, UTMD is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
UTMD vs BLCO Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, BLCO has a market cap of 6.9B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while BLCO trades at $19.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas BLCO's P/E ratio is 29.85. In terms of profitability, UTMD's ROE is +0.09%, compared to BLCO's ROE of -0.02%. Regarding short-term risk, UTMD is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
UTMD vs TFX Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, TFX has a market cap of 6.4B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while TFX trades at $161.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas TFX's P/E ratio is 18.47. In terms of profitability, UTMD's ROE is +0.09%, compared to TFX's ROE of +0.10%. Regarding short-term risk, UTMD is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
UTMD vs MMSI Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while MMSI trades at $84.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas MMSI's P/E ratio is 21.58. In terms of profitability, UTMD's ROE is +0.09%, compared to MMSI's ROE of +0.10%. Regarding short-term risk, UTMD is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
UTMD vs ICUI Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ICUI has a market cap of 4.3B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ICUI trades at $172.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ICUI's P/E ratio is 21.54. In terms of profitability, UTMD's ROE is +0.09%, compared to ICUI's ROE of +0.03%. Regarding short-term risk, UTMD is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ICUI's competition here
Stevanato Group S.p.A. (NYSE: STVN)
UTMD vs STVN Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, STVN has a market cap of 4.3B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while STVN trades at $15.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas STVN's P/E ratio is 23.71. In terms of profitability, UTMD's ROE is +0.09%, compared to STVN's ROE of +0.09%. Regarding short-term risk, UTMD is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STVN's competition here
Envista Holdings Corp (NYSE: NVST)
UTMD vs NVST Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, NVST has a market cap of 3.7B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while NVST trades at $22.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas NVST's P/E ratio is 15.61. In terms of profitability, UTMD's ROE is +0.09%, compared to NVST's ROE of +0.21%. Regarding short-term risk, UTMD is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
UTMD vs PLSE Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, PLSE has a market cap of 3.4B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while PLSE trades at $45.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas PLSE's P/E ratio is -38.62. In terms of profitability, UTMD's ROE is +0.09%, compared to PLSE's ROE of -0.78%. Regarding short-term risk, UTMD is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
UTMD vs ATRC Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ATRC trades at $55.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ATRC's P/E ratio is 1718.94. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRC's ROE of +0.03%. Regarding short-term risk, UTMD is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
UTMD vs BLFS Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas BLFS's P/E ratio is 37.49. In terms of profitability, UTMD's ROE is +0.09%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, UTMD is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
UTMD vs AZTA Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, AZTA has a market cap of 1.9B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while AZTA trades at $44.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas AZTA's P/E ratio is 106.71. In terms of profitability, UTMD's ROE is +0.09%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, UTMD is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check AZTA's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
UTMD vs LMAT Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, LMAT has a market cap of 1.7B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while LMAT trades at $73.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas LMAT's P/E ratio is 27.03. In terms of profitability, UTMD's ROE is +0.09%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, UTMD is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check LMAT's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
UTMD vs XRAY Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, XRAY has a market cap of 1.7B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while XRAY trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas XRAY's P/E ratio is 5.80. In terms of profitability, UTMD's ROE is +0.09%, compared to XRAY's ROE of -0.09%. Regarding short-term risk, UTMD is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check XRAY's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
UTMD vs KMTS Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while KMTS trades at $25.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas KMTS's P/E ratio is -9.48. In terms of profitability, UTMD's ROE is +0.09%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, UTMD is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
UTMD vs STAA Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while STAA trades at $24.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas STAA's P/E ratio is 42.54. In terms of profitability, UTMD's ROE is +0.09%, compared to STAA's ROE of +0.00%. Regarding short-term risk, UTMD is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
UTMD vs ATRI Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ATRI's P/E ratio is 64.50. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, UTMD is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATRI's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
UTMD vs MMEDV Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas MMEDV's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.09%, compared to MMEDV's ROE of N/A. Regarding short-term risk, UTMD is more volatile compared to MMEDV. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MMEDV's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
UTMD vs ANGO Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ANGO has a market cap of 454.6M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ANGO trades at $10.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ANGO's P/E ratio is -27.72. In terms of profitability, UTMD's ROE is +0.09%, compared to ANGO's ROE of -0.19%. Regarding short-term risk, UTMD is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
UTMD vs EMBC Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, EMBC has a market cap of 340.8M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while EMBC trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas EMBC's P/E ratio is 2.31. In terms of profitability, UTMD's ROE is +0.09%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, UTMD is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
UTMD vs SMTI Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, SMTI has a market cap of 300.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while SMTI trades at $32.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas SMTI's P/E ratio is -545.17. In terms of profitability, UTMD's ROE is +0.09%, compared to SMTI's ROE of -0.42%. Regarding short-term risk, UTMD is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
UTMD vs OSUR Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, OSUR has a market cap of 239.6M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while OSUR trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas OSUR's P/E ratio is -5.03. In terms of profitability, UTMD's ROE is +0.09%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, UTMD is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check OSUR's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
UTMD vs PDEX Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, PDEX has a market cap of 202.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while PDEX trades at $63.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas PDEX's P/E ratio is 17.33. In terms of profitability, UTMD's ROE is +0.09%, compared to PDEX's ROE of +0.26%. Regarding short-term risk, UTMD is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check PDEX's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
UTMD vs NNNN Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, NNNN has a market cap of 150.1M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while NNNN trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas NNNN's P/E ratio is 22.80. In terms of profitability, UTMD's ROE is +0.09%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, UTMD is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
UTMD vs KRMD Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, KRMD has a market cap of 138.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas KRMD's P/E ratio is -79.75. In terms of profitability, UTMD's ROE is +0.09%, compared to KRMD's ROE of -0.00%. Regarding short-term risk, UTMD is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
UTMD vs STXS Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, STXS has a market cap of 95M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while STXS trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas STXS's P/E ratio is -5.54. In terms of profitability, UTMD's ROE is +0.09%, compared to STXS's ROE of -1.16%. Regarding short-term risk, UTMD is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
UTMD vs AKYA Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas AKYA's P/E ratio is -1.34. In terms of profitability, UTMD's ROE is +0.09%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, UTMD is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
UTMD vs STSS Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas STSS's P/E ratio is -0.02. In terms of profitability, UTMD's ROE is +0.09%, compared to STSS's ROE of -0.99%. Regarding short-term risk, UTMD is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
UTMD vs OMIC Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas OMIC's P/E ratio is -0.58. In terms of profitability, UTMD's ROE is +0.09%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, UTMD is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
UTMD vs IGAP Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas IGAP's P/E ratio is -10.52. In terms of profitability, UTMD's ROE is +0.09%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, UTMD is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
UTMD vs POCI Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, POCI has a market cap of 45.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while POCI trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas POCI's P/E ratio is -8.98. In terms of profitability, UTMD's ROE is +0.09%, compared to POCI's ROE of -0.14%. Regarding short-term risk, UTMD is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check POCI's competition here
Daxor Corporation (NASDAQ: DXR)
UTMD vs DXR Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, DXR has a market cap of 43.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while DXR trades at $7.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas DXR's P/E ratio is 6.05. In terms of profitability, UTMD's ROE is +0.09%, compared to DXR's ROE of +0.13%. Regarding short-term risk, UTMD is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check DXR's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
UTMD vs HBIO Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, HBIO has a market cap of 39.6M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while HBIO trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas HBIO's P/E ratio is -24.03. In terms of profitability, UTMD's ROE is +0.09%, compared to HBIO's ROE of -1.30%. Regarding short-term risk, UTMD is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
UTMD vs NEPH Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, NEPH has a market cap of 28.7M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while NEPH trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas NEPH's P/E ratio is 44.00. In terms of profitability, UTMD's ROE is +0.09%, compared to NEPH's ROE of +0.17%. Regarding short-term risk, UTMD is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NEPH's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
UTMD vs ZJYL Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ZJYL has a market cap of 26.2M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ZJYL trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ZJYL's P/E ratio is 22.91. In terms of profitability, UTMD's ROE is +0.09%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ZJYL's competition here
Invacare Corporation (NYSE: IVC)
UTMD vs IVC Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas IVC's P/E ratio is -0.79. In terms of profitability, UTMD's ROE is +0.09%, compared to IVC's ROE of -0.46%. Regarding short-term risk, UTMD is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check IVC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
UTMD vs MLSS Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, MLSS has a market cap of 21.7M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while MLSS trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas MLSS's P/E ratio is -4.79. In terms of profitability, UTMD's ROE is +0.09%, compared to MLSS's ROE of -1.22%. Regarding short-term risk, UTMD is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check MLSS's competition here
Retractable Technologies, Inc. (AMEX: RVP)
UTMD vs RVP Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, RVP has a market cap of 16.7M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while RVP trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas RVP's P/E ratio is -4.65. In terms of profitability, UTMD's ROE is +0.09%, compared to RVP's ROE of -0.08%. Regarding short-term risk, UTMD is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
UTMD vs BNGO Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, BNGO has a market cap of 11.5M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while BNGO trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas BNGO's P/E ratio is -0.27. In terms of profitability, UTMD's ROE is +0.09%, compared to BNGO's ROE of -0.85%. Regarding short-term risk, UTMD is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
UTMD vs FEMY Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, FEMY has a market cap of 10.7M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while FEMY trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas FEMY's P/E ratio is -0.28. In terms of profitability, UTMD's ROE is +0.09%, compared to FEMY's ROE of -1.14%. Regarding short-term risk, UTMD is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
UTMD vs LUCY Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, LUCY has a market cap of 6.2M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while LUCY trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas LUCY's P/E ratio is -0.55. In terms of profitability, UTMD's ROE is +0.09%, compared to LUCY's ROE of -1.03%. Regarding short-term risk, UTMD is similarly volatile compared to LUCY. This indicates similar risk in terms of short-term price fluctuations for UTMD.Check LUCY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
UTMD vs RGNT Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, RGNT has a market cap of 5.1M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while RGNT trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas RGNT's P/E ratio is -0.30. In terms of profitability, UTMD's ROE is +0.09%, compared to RGNT's ROE of N/A. Regarding short-term risk, UTMD is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
UTMD vs NSTG Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas NSTG's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.09%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, UTMD is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
UTMD vs POAI Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas POAI's P/E ratio is -0.38. In terms of profitability, UTMD's ROE is +0.09%, compared to POAI's ROE of -3.50%. Regarding short-term risk, UTMD is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check POAI's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
UTMD vs CUPR Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, CUPR has a market cap of 3.2M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while CUPR trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas CUPR's P/E ratio is -0.88. In terms of profitability, UTMD's ROE is +0.09%, compared to CUPR's ROE of -0.85%. Regarding short-term risk, UTMD is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check CUPR's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
UTMD vs MHUA Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas MHUA's P/E ratio is 0.25. In terms of profitability, UTMD's ROE is +0.09%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, UTMD is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
UTMD vs GMVD Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas GMVD's P/E ratio is -0.01. In terms of profitability, UTMD's ROE is +0.09%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, UTMD is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
UTMD vs GMVDW Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas GMVDW's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.09%, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, UTMD is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
UTMD vs NXGL Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while NXGL trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas NXGL's P/E ratio is -4.51. In terms of profitability, UTMD's ROE is +0.09%, compared to NXGL's ROE of -1.52%. Regarding short-term risk, UTMD is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
UTMD vs AVGR Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas AVGR's P/E ratio is -0.05. In terms of profitability, UTMD's ROE is +0.09%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, UTMD is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
UTMD vs NXGLW Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, NXGLW has a market cap of 550.6K. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, UTMD's ROE is +0.09%, compared to NXGLW's ROE of -1.52%. Regarding short-term risk, UTMD is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
UTMD vs LUCYW Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas LUCYW's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.09%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, UTMD is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check LUCYW's competition here
KICK Space Data Center & Infrastructure Index ETF (NASDAQ: SDC)
UTMD vs SDC Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, SDC has a market cap of 217.6K. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while SDC trades at $21.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas SDC's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.09%, compared to SDC's ROE of +0.00%. Regarding short-term risk, UTMD is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check SDC's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
UTMD vs ATRS Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ATRS's P/E ratio is 14.95. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, UTMD is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
UTMD vs ALOG Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas ALOG's P/E ratio is 40.93. In terms of profitability, UTMD's ROE is +0.09%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, UTMD is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
UTMD vs IVTY Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas IVTY's P/E ratio is -3.80. In terms of profitability, UTMD's ROE is +0.09%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, UTMD is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IVTY's competition here
IntriCon Corporation (NASDAQ: IIN)
UTMD vs IIN Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, IIN has a market cap of 0. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas IIN's P/E ratio is 226.45. In terms of profitability, UTMD's ROE is +0.09%, compared to IIN's ROE of -0.00%. Regarding short-term risk, UTMD is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
UTMD vs HRC Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, HRC has a market cap of 0. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas HRC's P/E ratio is 41.92. In terms of profitability, UTMD's ROE is +0.09%, compared to HRC's ROE of +0.14%. Regarding short-term risk, UTMD is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HRC's competition here
Apria, Inc. (NASDAQ: APR)
UTMD vs APR Comparison November 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 198.4M. In comparison, APR has a market cap of 0. Regarding current trading prices, UTMD is priced at $69.49 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 20.59, whereas APR's P/E ratio is 22.59. In terms of profitability, UTMD's ROE is +0.09%, compared to APR's ROE of +9.81%. Regarding short-term risk, UTMD is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check APR's competition here